TSPT Share Price

Open 1.71 Change Price %
High 1.79 1 Day -0.04 -2.30
Low 1.55 1 Week 0.00 0.00
Close 1.70 1 Month 0.00 0.00
Volume 63501 1 Year 0.00 0.00
52 Week High 269.34
52 Week Low 141.05
TSPT Important Levels
Resistance 2 1.92
Resistance 1 1.83
Pivot 1.68
Support 1 1.57
Support 2 1.48
NASDAQ USA Most Active Stocks
SIRI 4.30 -5.49%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
QQQ 115.67 0.17%
WRES 0.09 0.00%
More..
NASDAQ USA Top Gainers Stocks
QKLS 0.21 110.00%
LOCM 0.09 50.00%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
PERF 1.90 22.58%
ASNA 7.01 20.24%
SBSA 4.60 17.95%
CEMP 7.55 15.27%
XXIA 15.55 14.76%
More..
NASDAQ USA Top Losers Stocks
PTIX 0.00 -100.00%
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
AMCF 0.03 -50.00%
OPXAW 0.01 -50.00%
VALV 0.03 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
More..

Transcept Pharmaceuticals, Inc. (NASDAQ: TSPT)

TSPT Technical Analysis 5
As on 30th Oct 2014 TSPT Share Price closed @ 1.70 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 2.75 & Strong Sell for SHORT-TERM with Stoploss of 2.05 we also expect STOCK to react on Following IMPORTANT LEVELS.
TSPT Target for December
1st Target up-side N/A
2nd Target up-side N/A
3rd Target up-side N/A
1st Target down-side N/A
2nd Target down-side N/A
3rd Target down-side N/A
TSPT Other Details
Segment EQ
Market Capital 98759384.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.transcept.com
TSPT Address
TSPT
1003 West Cutting Boulevard
Suite 110
Point Richmond, CA 94804
United States
Phone: 510-215-3500
Interactive Technical Analysis Chart Transcept Pharmaceuticals, Inc. ( TSPT NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Transcept Pharmaceuticals, Inc.
TSPT Business Profile
Transcept Pharmaceuticals, Inc. (Transcept) is a specialty pharmaceutical company focused on the development and commercialization of products that address therapeutic needs in the field of neuroscience. In November 2011, the United States Food and Drug Administration (FDA) approved its new drug application (NDA) for Intermezzo (zolpidem tartrate) sublingual tablet C-IV for use as needed for the treatment of insomnia when a middle-of-the-night awakening is followed by difficulty returning to sleep. In March 2011, the Company began a Phase II study of TO-2061, a low dose of ondansetron adjunctive treatment for patients with obsessive compulsive disorder (OCD), who has not adequately responded to first-line therapy.